PRVCF Stock Chart & Stats
$0.01
<$0.01(19.78%)
At close: 4:00 PM EDT
$0.01
<$0.01(19.78%)
Day’s Range― - ―
52-Week Range<$0.01 - $0.04
Previous CloseN/A
Volume46.73K
Average Volume (3M)15.64K
Market Cap
$9.21M
Enterprise Value$13.85
Total Cash (Recent Filing)$35.66K
Total Debt (Recent Filing)$4.84M
Price to Earnings (P/E)―
Beta-0.14
Next Earnings
Nov 19, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding638,186,950
10 Day Avg. Volume13,025
30 Day Avg. Volume15,640
Financial Highlights & Ratios
PEG Ratio-0.33
Price to Book (P/B)-2.28
Price to Sales (P/S)0.00
P/FCF Ratio-8.26
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Drug-delivery R&D PlatformPreveCeutical has a defined life-sciences platform spanning therapeutic research, nutraceutical products, and drug-delivery systems. This breadth creates multiple development avenues and gives the company intellectual-property-based opportunities to advance formulations or delivery technologies over the next several quarters.
Licensing Monetization PotentialThe business model includes potential licensing and partnering of drug-delivery technologies and therapeutic formulations, providing a route to monetize intellectual property without relying exclusively on direct product sales. Successful commercialization could broaden future revenue sources and improve operating leverage.
Asset Base ImprovedImprovement in total assets versus prior years is a modest constructive balance-sheet development. If maintained, a larger asset base could support research activities and future commercialization, although this benefit is limited because the company still has negative equity and substantial leverage.
Bears Say
No Demonstrated RevenueZero reported revenue across available periods shows that the company has not yet demonstrated commercial traction from its product candidates or intellectual property. Continued losses without an established revenue base increase dependence on future commercialization, financing, or partnering outcomes.
Negative Equity And LeveragePersistent negative equity and debt that exceeds the asset base indicate a weak capital structure and limited financial flexibility. This condition can constrain investment in research and commercialization while increasing reliance on external funding and making the business less resilient to setbacks.
Persistent Cash BurnOngoing operating and free-cash-flow losses show that the company is not self-funding its activities. The latest deterioration in free cash flow suggests funding needs may be rising, increasing the risk that future operations require additional capital before products generate meaningful cash.
PreveCeutical Medical News
PRVCF FAQ
What was PreveCeutical Medical Inc’s price range in the past 12 months?
PreveCeutical Medical Inc lowest stock price was <$0.01 and its highest was $0.04 in the past 12 months.
What is PreveCeutical Medical Inc’s market cap?
PreveCeutical Medical Inc’s market cap is $9.21M.
When is PreveCeutical Medical Inc’s upcoming earnings report date?
PreveCeutical Medical Inc’s upcoming earnings report date is Nov 19, 2026 which is in 67 days.
How were PreveCeutical Medical Inc’s earnings last quarter?
PreveCeutical Medical Inc released its earnings results on Aug 28, 2026. The company reported -$0.001 earnings per share for the quarter.
Is PreveCeutical Medical Inc overvalued?
According to Wall Street analysts PreveCeutical Medical Inc’s price is currently Overvalued.
Does PreveCeutical Medical Inc pay dividends?
PreveCeutical Medical Inc does not currently pay dividends.
What is PreveCeutical Medical Inc’s EPS estimate?
PreveCeutical Medical Inc’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PreveCeutical Medical Inc have?
PreveCeutical Medical Inc has 638,186,950 shares outstanding.
What happened to PreveCeutical Medical Inc’s price movement after its last earnings report?
PreveCeutical Medical Inc reported an EPS of -$0.001 in its last earnings report. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of PreveCeutical Medical Inc?
Currently, no hedge funds are holding shares in PRVCF
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
PreveCeutical Medical Inc
PreveCeutical Medical Inc. is a health sciences firm dedicated to creating preventative and therapeutic solutions, employing compounds that are either organic or identical to natural substances. Its robust product pipeline features the Cannabinoid Sol-Gel Delivery system, a cannabinoid-based technology designed for nose-to-brain delivery, aiming to alleviate symptoms associated with pain, inflammation, epileptic seizures, and diverse neurological conditions. Also in development is the BSV Peptide Program, which focuses on hindering cancer's advancement, alongside a non-addictive analgesic for effective pain relief. The company is also progressing with a Dual Gene Therapy project to address type 2 diabetes and obesity. Complementing these initiatives, PreveCeutical is involved in the creation of various products derived from medicinal cannabis. The company is headquartered in Vancouver, Canada.
Technical Analysis
Rapid Dose Therapeutics Corp
―
BetterLife Pharma
―
―
MYND Life Sciences
―
PharmAla Biotech Holdings, Inc.
―